Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Status:
Not yet recruiting
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
Ovarian cancer was mostly diagnosed at late stage (III/IV) with high rate of recurrence after
first line of therapy by optimal cytoreductive sugery and 6cycle of TP chemotherapy. There is
no standard maintainance therapy for BRCA1/2 wide-type ovarian cancer. We developed an
adjuvant chemotherapy of "three steps" (ACTS). It is adding CTX+VP-16(second step) 6cycle and
CTX+CBP(third steps) to firstline chemotherapy (first step). The aim of this study is to
verify the effectivity and safety of ACTS in BRCA1/2 wide-type ovarian cancer patients.